LRP1 and Alzheimer disease: Importantly, blocking low-density lipoprotein receptor-related protein 1 (LRP-1) or activating epsilon protein kinase C epsilon (PKCε) can reverse these effects, suggesting potential targets for restoring BDNF expression in AD [153,154].